Diabetes Patients Struggle as Novo Nordisk Stops Levemir Sales in U.S.

Novo Nordisk's decision to halt U.S. sales of its long-acting insulin Levemir has left many diabetes patients scrambling for alternative treatments. Despite Novo's assertion that there are other viable options, patients and doctors report difficulties in finding suitable replacements, leading to lobbying efforts to keep Levemir on the market.

Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left many diabetes patients and their physicians facing a tough transition, according to reports from a dozen U.S. states. The Danish pharmaceutical giant announced in November that sales of Levemir would cease by the end of 2024, citing global manufacturing constraints and diminishing insurance coverage.

Patients with type 1 diabetes and parents of young patients have resorted to stockpiling Levemir supplies, even using vials past their expiration dates. They argue that Levemir is better suited for active lifestyles and youth, allowing for more frequent dose adjustments. Cases of hypoglycemia and rapid blood sugar fluctuations have been reported with alternative insulins.

The decision comes as Novo shifts focus to its lucrative weight-loss injection Wegovy, raising concerns that less profitable insulins are being deprioritized. Advocacy groups and lawmakers are pushing Novo to continue Levemir production or facilitate the introduction of cheaper, biosimilar alternatives.

(With inputs from agencies.)